Coherus BioSciences (CHRS) Tops Q4 EPS by 20c

Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $45.35 million versus the consensus estimate of $48.41 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?